^
Association details:
| Biomarker: | HER-2 negative + PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + retlirafusp alfa (SHR-1701) (PD-L1 inhibitor, TGF-β R2 kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1026MO - A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Published date:
10/16/2023
Excerpt:
This is a multicenter, open-label, phase 1b/2 study...pts with advanced gastric and gastroesophageal junction cancer (GC/GEJC), PD-L1 CPS ≥1, HER2 negative... With a median follow-up of 8.4 mos, the ORR was 21.1%, 33.3%, and 10.0% in the three cohorts, respectively...SHR-1701 plus BEV showed encouraging antitumor activity with a favorable safety profile in pts with advanced GC/GEJC and nsqNSCLC.
Trial ID:
